What You Should Know:
– Surescripts, the leading health information network in the United States, has acquired ActiveRADAR, a clinical intelligence company focused on identifying therapeutic alternatives for prescriptions. Financial details of the acquisition were not disclosed.
– The acquisition is expected to have a positive impact on medication adherence, patient-provider engagement, and the overall patient experience by providing better alternatives and reducing waste and costs.
– Surescripts plans to use ActiveRADAR’s extensive catalog of therapeutic alternatives data to enhance the value delivered by its data, reduce drug spend, and provide more alternatives when deploying prescription pricing information to providers.
ActiveRADAR’s Background
ActiveRADAR offers evidence-based, formulary-specific therapeutic alternatives, along with dosage strengths, quantities, and plan-specific patient and health plan costs. They cover more than 165 therapeutic categories, including specialty drugs, and provide clinical and economic value data on medication alternatives. ActiveRADAR’s solutions have demonstrated the potential to reduce costs for employers and employees by 15 to 20%, primarily through targeted savings opportunities and minimizing member disruption.
“Providing faster access to insights and optimizing the value delivered by our data are two of our biggest priorities, so we’re thrilled to have the ActiveRADAR team joining Surescripts,” said Dr. Lynne Nowak, Chief Data & Analytics Officer of Surescripts. “With access to their extensive catalog of therapeutic alternatives data, we can reduce drug spend and help provide more alternatives when deploying prescription pricing information to providers.”
Data Optimization
Surescripts plans to use ActiveRADAR’s extensive catalog of therapeutic alternatives data to enhance the value delivered by its data, reduce drug spend, and provide more alternatives when deploying prescription pricing information to providers.
